ANGO Key Stats
- AngioDynamics (ANGO) NanoKnife Receives IDE Approval from FDA Street Insider Jun 18
- FDA Grants Prostate IDE Approval for AngioDynamics' NanoKnife System GlobeNewswire Jun 18
- Premier Selects AngioDynamics' BioFlo PICC as a Breakthrough Technology GlobeNewswire Jun 12
- Nasdaq stocks posting largest percentage decreases May 28
- ANGIODYNAMICS INC Files SEC form 8-K, Change in Directors or Principal Officers May 28
- AngioDynamics to Present at Jefferies 2013 Global Healthcare Conference GlobeNewswire May 28
- ANGIODYNAMICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statem... May 21
- Taking a Closer Look at Medical Device and Product Companies, as Some are Genera... May 17
- A Comprehensive Overview Of Active Electroporation Cancer Trials May 14
- AngioDynamics to Present at UBS Global Healthcare Conference GlobeNewswire May 14
ANGO Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). AngioDynamics is down 9.34% over the last year vs S&P 500 Total Return up 23.89%, BSD Medical Corporation down 25.43%, and Boston Scientific up 62.63%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Pro Ratings for ANGO
Pro Report PDF for ANGO
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download ANGO Pro Report PDF
Pro Strategies Featuring ANGO
Did AngioDynamics make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.